In support of this notion, pharmacological or genomic approaches targeting ATF6 induced a significant decrease in EGF transcription and angiogenesis-stimulating activities in SCCs, effectively suppressing the SCC-derived tumor growth. The gene discussed is EGF; the disease is neoplasm.